# Ruxolitinib In GvHD

> **NCT02396628** · PHASE2 · TERMINATED · sponsor: **Prof. Dr. Nikolas von Bubnoff** · enrollment: 22 (actual)

## Conditions studied

- Graft vs Host Disease

## Interventions

- **DRUG:** Experimental intervention
- **DRUG:** Standard treatment

## Key facts

- **NCT ID:** NCT02396628
- **Lead sponsor:** Prof. Dr. Nikolas von Bubnoff
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-29
- **Primary completion:** 2019-11-15
- **Final completion:** 2019-11-15
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** impossibility to recruit in the BAT arm
- **Last updated:** 2019-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02396628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02396628, "Ruxolitinib In GvHD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02396628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*